Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-87M | $-88M | $-68M | -39.2% | 105.0% | -7.3% |
| 2024 | $0M | $-95M | $-95M | $-80M | -77.0% | -95.3% | 7.5% |
| 2023 | $0M | $-88M | $-88M | $-76M | -45.6% | -726.5% | 4.4% |
| 2022 | $-0M | $-84M | $-85M | $-63M | -45.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0.04 |
| Operating Revenue | 0.04 |
| Operating Expense | 94.53 |
| Research And Development | 66.43 |
| Selling General And Administration | 28.10 |
| Total Expenses | 94.53 |
| Operating Income | -94.49 |
| Total Operating Income As Reported | -94.49 |
| EBITDA | -87.03 |
| Normalized EBITDA | -87.03 |
| EBIT | -87.14 |
| Interest Income | 7.54 |
| Interest Expense | 1.64 |
| Net Interest Income | 5.90 |
| Other Non Operating Income Expenses | -0.19 |
| Other Income Expense | -0.19 |
| Interest Income Non Operating | 7.54 |
| Interest Expense Non Operating | 1.64 |
| Net Non Operating Interest Income Expense | 5.90 |
| Pretax Income | -88.77 |
| Tax Provision | -0.68 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -88.09 |
| Net Income From Continuing And Discontinued Operation | -88.09 |
| Net Income From Continuing Operation Net Minority Interest | -88.09 |
| Net Income | -88.09 |
| Net Income Common Stockholders | -88.09 |
| Net Income Including Noncontrolling Interests | -88.09 |
| Normalized Income | -88.09 |
| Diluted NI Availto Com Stockholders | -88.09 |
| Basic Average Shares | 88.10 |
| Diluted Average Shares | 88.10 |
| Reconciled Depreciation | 0.11 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Impairment Of Capital Assets | - |
| General And Administrative Expense | 28.10 |
| Other Gand A | 28.10 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Altimmune, Inc.this co. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Rigel Pharmaceuticals, Inc. | RIGL | $560M | 1.52 | 1.43 | 93.8% | 4.35 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $560M |
| - |
| - |
| - |
| - |
| 23.30 |
| -2.14 |
| -9.2% |
| 9.00 |
| Cytek Biosciences, Inc. | CTKB | $559M | -8.40 | 1.64 | -19.5% | -28.29 |
| Cerus Corporation | CERS | $559M | - | 8.70 | -24.3% | - |
| NeuroPace, Inc. | NPCE | $556M | -25.92 | 29.24 | -112.8% | -50.21 |
| Fulgent Genetics, Inc. | FLGT | $554M | -9.15 | 0.50 | -5.4% | -11.16 |
| Peer Median | - | 1.52 | 1.92 | -7.3% | 4.35 | |